Sepsis and Septic Shock

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, while septic shock represents sepsis with hypotension requiring vasopressor support and/or elevated lactate despite fluid resuscitation. Previously defined by SIRS criteria, sepsis is now operationalized by the Sepsis-3 criteria (2016), which use qSOFA or SOFA scores to identify high-risk patients. Sepsis affects approximately 1.7 million adults annually in the United States with in-hospital mortality of 15-40%, making it a leading cause of ICU admission and death. The incidence increases dramatically with age (>10-fold increase in those >65 years), immunosuppression, and underlying comorbidities including diabetes, malignancy, and chronic organ disease. Early recognition and rapid initiation of antibiotics within the first hour of presentation dramatically improve outcomes, making sepsis recognition essential knowledge for USMLE Step 2 CK. Understanding the pathophysiologic cascade from initial infection through organ dysfunction is critical for clinical decision-making and board examinations.

Sepsis represents a dysregulated bidirectional immune response characterized by simultaneous hyperinflammation and immunosuppression, creating a paradoxical state where the host immune response causes tissue damage and organ dysfunction while simultaneously becoming unable to effectively control infection.

The pathogenic cascade begins when pathogen-associated molecular patterns (PAMPs) from gram-positive bacteria (lipoteichoic acid), gram-negative bacteria (lipopolysaccharide [LPS]/endotoxin), or fungi (β-glucans, mannans) are recognized by innate immune pattern recognition receptors, particularly toll-like receptors (TLRs) on macrophages, dendritic cells, and endothelial cells. TLR4, the primary sensor for LPS, undergoes conformational change and recruits MyD88 and TRIF adapter proteins, activating both the canonical NF-κB and MAPK signaling cascades simultaneously. This triggers rapid transcription of pro-inflammatory cytokine genes including TNF-α, IL-1β, and IL-6, which serve as the primary drivers of the early systemic inflammatory response. Damage-associated molecular patterns (DAMPs) released from injured tissue—including high-mobility group box 1 (HMGB1) protein, ATP, DNA fragments, and heat-shock proteins—further amplify TLR signaling and perpetuate inflammation even as bacterial burden may be controlled.

The massive surge of pro-inflammatory cytokines creates a self-perpetuating inflammatory cascade. TNF-α acts as a master regulator, increasing endothelial expression of adhesion molecules (ICAM-1, VCAM-1, selectins) that promote neutrophil adhesion and extravasation into tissues. IL-1β acts synergistically with TNF-α to induce COX-2 and NOS2, driving production of prostaglandins (especially PGE2) and nitric oxide (NO), which causes profound vasodilation and distributive shock. IL-6 correlates with disease severity and drives hepatic acute-phase protein synthesis while promoting further immune activation. These cytokines trigger activation of the contact cascade system (including Hageman factor, bradykinin), complement system (especially the alternative pathway through LPS-induced mannose-binding lectin), and coagulation cascade, creating a state of systemic endothelial activation. Critically, TNF-α and IL-1β induce expression of inducible NOS (iNOS/NOS2), leading to excessive nitric oxide production that causes vasodilation refractory to catecholamines, mitochondrial dysfunction, and cellular injury—this is the fundamental mechanism of distributive shock in sepsis.

Sepsis causes profound endothelial cell injury through multiple mechanisms, resulting in increased vascular permeability and loss of normal vascular autoregulation. NO-mediated vasodilation increases hydrostatic pressure while increased VEGF, histamine, and bradykinin signaling cause direct endothelial cell contraction and junction disruption, widening intercellular gaps. Activated neutrophils adhere to endothelium via upregulated adhesion molecules and release proteolytic enzymes (elastase, collagenase) and reactive oxygen species (ROS) that degrade the glycocalyx—the protective carbohydrate layer lining the endothelium. This glycocalyx shedding releases syndecan-1, hyaluronic acid, and other proteoglycans into the circulation, further increasing permeability and perpetuating inflammation. The result is massive third-spacing of fluid from intravascular to interstitial space, causing profound hypovolemia despite adequate fluid resuscitation and contributing to multi-organ dysfunction. The endothelial leak is particularly prominent in the lungs (causing ARDS), gut (facilitating bacterial translocation), and kidneys (impairing perfusion).

Paradoxically, as hyperinflammation progresses, patients develop profound immunosuppression characterized by T cell exhaustion, apoptosis, and functional defects. IL-10 and TGF-β, released initially as counter-regulatory anti-inflammatory cytokines, become pathologically elevated and promote a shift toward T regulatory cells and alternative macrophage activation. CD4+ and CD8+ T cells undergo increased apoptosis via Fas ligand engagement, leading to lymphopenia that strongly correlates with mortality. Monocytes display downregulation of HLA-DR molecules and shift toward an anti-inflammatory/alternatively activated phenotype with reduced TNF-α production capacity. Natural killer (NK) cells become dysfunctional with impaired cytotoxic activity and IFN-γ production. This immunosuppression accounts for the susceptibility to secondary infections (fungal, opportunistic) in survivors of severe sepsis and the failure of some immunostimulatory therapies.

Sepsis causes profound mitochondrial injury through multiple mechanisms, including direct damage from ROS and peroxynitrite (a NO/superoxide product), mitochondrial Ca2+ overload, and inflammatory mediator-induced opening of the mitochondrial permeability transition pore. This impairs oxidative phosphorylation and ATP production, causing cellular bioenergetic failure even in normoxic tissue—"cytopathic hypoxia." Damaged mitochondria release cytochrome c, triggering apoptosis through the intrinsic pathway. The combination of impaired ATP production and excessive metabolic demand leads to the characteristic septic lactate elevation, which reflects both tissue hypoperfusion and mitochondrial dysfunction. Notably, sepsis can cause multi-organ dysfunction without profound hypotension due to this mitochondrial injury, explaining why some patients with "cold sepsis" (adequate perfusion pressure) still develop organ failure.

Sepsis activates the coagulation cascade through TF/Factor VIIa complex activation (induced by LPS and cytokines), complement activation, and endothelial expression of phosphatidylserine (normally on the inner membrane leaflet). This creates a pathologic "thromboinflammation" where systemic activation of coagulation leads to consumption of platelets and clotting factors (disseminated intravascular coagulation [DIC] in severe cases). Simultaneously, hyperfibrinolysis may occur due to excessive tPA release, creating a paradoxical bleeding tendency. Tissue factor-bearing microparticles generated by activated endothelium, platelets, and leukocytes propagate coagulation systemically. Thrombin itself acts as a pro-inflammatory mediator via protease-activated receptors (PARs), amplifying the immune response. Excessive microvascular thrombosis impairs tissue perfusion and contributes to organ failure, particularly in kidneys, lungs, and liver.

Sepsis causes multi-organ dysfunction through the integrated effects of hypotension/hypoperfusion, mitochondrial injury, inflammation, and microvascular thrombosis. In the lungs, direct ALI/ARDS develops through neutrophil sequestration, endothelial/epithelial injury, glycocalyx shedding, and pulmonary edema, with neutrophil elastase and TNF-α playing central roles. In the kidneys, decreased renal perfusion pressure (despite systemic hypotension or normal systemic pressure), tubular obstruction by cellular debris, inflammatory injury, and endothelial dysfunction all contribute to acute tubular necrosis and AKI; sepsis is now the leading cause of AKI in ICU patients. Hepatic dysfunction results from impaired hepatic blood flow (microvascular dysfunction), direct TNF-α-mediated hepatocyte injury, and mitochondrial dysfunction. Encephalopathy in sepsis reflects a combination of cerebral hypoperfusion, blood-brain barrier disruption, elevated lactate and ammonia, and direct neuroinflammation driven by TNF-α and IL-1β.

Gram-negative organisms, particularly Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae, account for approximately 50-60% of sepsis cases. These bacteria release endotoxin (LPS) from their outer membrane, which is the most potent TLR4 agonist and most direct trigger of the sepsis cascade. Gram-negative sepsis often originates from urinary tract infections (especially with indwelling catheters), intra-abdominal infections (perforated viscus, appendicitis, peritonitis), pneumonia, and intravascular catheter infections. The incidence of gram-negative sepsis, particularly with antibiotic-resistant organisms like extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE), has been increasing, especially in healthcare-associated settings.

Gram-positive organisms account for approximately 30-40% of sepsis cases, with Staphylococcus aureus (including methicillin-resistant strains [MRSA]) being the most common single organism causing sepsis. Other important gram-positive pathogens include Streptococcus pneumoniae (communityacquired pneumonia, meningitis), Group A Streptococcus (invasive skin/soft tissue infections), and Enterococcus species. S. aureus sepsis commonly arises from skin/soft tissue infections, healthcare-associated bloodstream infections (particularly central line-associated), and endocarditis. Gram-positive sepsis is often associated with more rapid progression to shock due to potent exotoxins; S. aureus produces alpha-toxin (α-hemolysin) and enterotoxins that directly damage tissues and trigger superantigen responses.

Candida species (particularly non-albicans species like C. glabrata, C. auris) account for 5-10% of sepsis cases and have increasing prevalence in critically ill populations. Sepsis from invasive candidiasis carries particularly high mortality (40-60%) and often occurs in patients with prolonged ICU stays, broad-spectrum antibiotics, central lines, abdominal surgery, or severe immunosuppression. Aspergillosis, cryptococcosis, and invasive mold infections are important causes in severely immunocompromised hosts (CD4 <50 cells/μL, prolonged neutropenia, hematologic malignancy).

Intra-abdominal infections (secondary peritonitis from perforation, appendicitis, pancreatitis) are frequently polymicrobial, combining gram-negative aerobes, gram-positive cocci, and anaerobes (Bacteroides fragilis, Clostridium species). Lung infections can involve atypical organisms including Legionella pneumophila (especially in hospitalized/immunocompromised patients), Mycoplasma, and Chlamydia. Viral sepsis, particularly from influenza and COVID-19, can occur with or without secondary bacterial superinfection and carries significant mortality, especially when combined with secondary bacterial infection.

Age >65 years increases sepsis risk 10-20 fold; immunologic senescence and increased comorbidities explain this. Male sex carries 20-30% higher mortality than female sex, possibly due to androgens suppressing immune function and differences in TLR signaling. Neonates (<3 months) have immature innate and adaptive immunity and high sepsis incidence from group B Streptococcus, gram-negative enteric organisms, and Listeria monocytogenes.

Severe immunosuppression dramatically increases sepsis risk from organisms that are frequently non-pathogenic in immunocompetent hosts. This includes: HIV infection (CD4 <200 cells/μL), malignancy and chemotherapy-induced neutropenia, solid organ transplantation with immunosuppressive medications, corticosteroid therapy (particularly doses >20 mg prednisone daily), and biologics including TNF-α inhibitors. Patients on TNF-α inhibitors are particularly susceptible to Mycobacterium tuberculosis reactivation, Listeria monocytogenes, and atypical infections.

Diabetes mellitus increases sepsis risk 2-3 fold through impaired neutrophil chemotaxis, opsonization, and phagocytosis; diabetic patients also have higher rates of urinary tract infections. Chronic kidney disease, chronic liver disease/cirrhosis, chronic obstructive pulmonary disease, and cardiovascular disease all independently increase sepsis risk and mortality. Cirrhotic patients have particularly high sepsis incidence and poor outcomes due to impaired synthetic function, opsonin deficiency, splenic dysfunction, and portal hypertension facilitating bacterial translocation.

Central venous catheters, urinary catheters, endotracheal tubes, and other indwelling devices disrupt mucosal barriers and create biofilms prone to colonization with hospital-acquired organisms including Acinetobacter, MRSA, Pseudomonas, and Candida. Prolonged hospitalization, prior antibiotic exposure, and ICU stay are major risk factors for healthcare-associated sepsis with resistant pathogens.

Surgery, trauma, burns, and abdominal perforation breach natural barriers and increase sepsis risk through inoculation of normally sterile sites with pathogenic organisms. Aspiration pneumonia risk increases with altered consciousness, dysphagia, and supine positioning.

Fever (core temperature >38.3°C or 101°F) is present in approximately 70-80% of sepsis cases and results from pyrogen-induced resetting of the hypothalamic set point by TNF-α, IL-1β, and IL-6. Notably, hypothermia (<36°C) is present in 10-15% of sepsis cases and actually carries worse prognosis than fever, suggesting overwhelming host response and impending organ failure. Elderly and immunosuppressed patients may present with minimal or absent fever despite severe sepsis, making reliance on temperature alone dangerous; a single elevated temperature in a previously febrile patient can be the only sign. Septic patients often report a prodrome of chills, rigors (shaking chills), and malaise for hours to days before presenting to medical attention.

Heart rate elevation (>90 bpm) occurs early through catecholamine release and inflammatory cytokine effects on SA nodal tissue. In septic shock, blood pressure drops as vasodilation and capillary leak overwhelm the compensatory increase in cardiac output; systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg, or requirement for vasopressor support despite fluid resuscitation defines septic shock. The shock state can be "warm" (warm extremities, bounding pulses, low systemic vascular resistance from excessive NO production) or "cold" (cool extremities, poor perfusion from reduced cardiac output or regional ischemia despite normal overall pressures). Some patients paradoxically develop high-output septic shock with clinical hyperdynamic features (low SVR, high cardiac output) but still have tissue hypoperfusion due to mitochondrial dysfunction.

Respiratory rate elevation (>20 breaths/minute) occurs early as metabolic acidosis and hypoxemia trigger chemoreceptor-mediated hyperventilation. Septic patients often present with respiratory alkalosis initially (from hyperventilation despite normal oxygen saturation), followed by metabolic acidosis with elevated lactate as mitochondrial dysfunction and tissue hypoperfusion develop. Progressive respiratory failure requiring

Sepsis is a clinical diagnosis — there is no single confirmatory test. The sequence is: recognize organ dysfunction, quantify perfusion failure with lactate, then identify the organism and the source.

Management follows the Surviving Sepsis Campaign (2021) Hour-1 bundle: measure lactate, obtain blood cultures, give broad-spectrum antibiotics, start crystalloid, and begin vasopressors for persisting hypotension.

Refractory shock and adjuncts: IV hydrocortisone (200 mg/day) is suggested for ongoing vasopressor requirement. Transfuse red cells restrictively at hemoglobin <7 g/dL; use lung-protective low-tidal-volume ventilation for sepsis-induced ARDS.

Avoid: hydroxyethyl starch, dopamine as first-line pressor, protocolized ScvO₂-targeted early goal-directed therapy, corticosteroids in sepsis without shock, and delaying antibiotics for imaging.